review

When people mention today’s medicine, precision plays one of the most significant roles and human lives are literally dependent on it. Hereby, any researches related to medicine are required to meet the top standards. The challenge nowadays is that any recommendations of researches can be posted online and used as a reference without being properly checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and attempted to create an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The main principle of this journal is related to Altmetric scores that are used as a quality indicator. That helps both readers and authors to quality-check publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication. ” Oncotarget website demonstrates a complete publications list with respective scores above 1

A promising new treatment option for the coronavirus was studied using a COVID-19 pseudovirus approach to observe its immune response to MEK inhibitors. 3D Illustration of COVID-19 3D Illustration of Coronavirus COVID-19 As researchers around the world are in the midst of searching for treatment options capable of combatting the COVID-19 virus, a single solution will not be effective for everyone—in both a logistical and biological sense. To produce different treatment options for populations of varying age and immune system health, numerous avenues are currently being explored. One potential treatment, studied by a coalition of researchers from Brown University, the Fox Chase Cancer Center, and Verastem Oncology, used a COVID-19 pseudovirus approach to demonstrate immune response to MEK inhibitors in a level 2 biosafe environment. The paper detailing this study has been published at Oncotarget.com. “For the current study, we have developed a pseudotyped SARS-CoV-2 virus which has a

When public discuss today’s medicine, precision plays one of the most crucial roles and people’s lives are directly dependent on it. Hence, any researches pertaining to medicine are necessary to comply with the top standards. The issue nowadays is that any conclusions of researches can be published online and used as a reference without being precisely verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this challenge and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality indicator. That assists both readers and authors to validate publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication. ” Oncotarget website demonstrates a full publications list with corresponding scores higher t

In the United States, the second leading cause of cancer related deaths in men is prostate cancer. While new research and therapies are advancing, a large percentage of patients with this disease continue to progress to the advanced stages. In the past, researchers have used biological indicators such as the prostate-specific antigen (PSA) to aid in early detection and diagnosis of prostate cancer. The PSA is an enzyme that plays a role in semen liquefaction, which is derived from prostate tissue and released by normal and tumor cells. While serum PSA quantities often correlate with prostate volume, researchers in this study say that PSA is not the most optimal prognostic indicator of prostate cancer. PSA serum levels are not only elevated in prostate cancer, but also in patients with benign prostatic hyperplasia. This has resulted in more patients incorrectly diagnosed with prostate cancer. Researchers based out of the United States conducted a study in hopes of solving this problem

When public refer to today’s medicine, accuracy plays one of the most important roles and human lives are literally dependent on it. Hereby, any researches pertaining to medicine are required to meet the top standards. The issue nowadays is that any recommendations of researches can be published online and used as a reference without being precisely checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and tried to create an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality indicator. That helps both readers and authors to quality-check publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication. ” Oncotarget website demonstrates a complete publications list with corresponding scores above 10

When general population speak of modern medicine, precision plays one of the most important roles and people’s lives are literally dependent on it. Likewise, any researches related to medicine are required to comply with the highest standards. The challenge today is that any conclusions of researches can be posted online and used as a reference without being precisely checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this issue and attempted to create an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality indicator. That assists both readers and authors to validate publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a full publications list with respective score

Oncotarget недавно опубликовал статью « Совместная работа для семьи: определение коамплификаций онкогенов HER при раке груди », в которой сообщается, что, несмотря на специфическое лечение, к сожалению, у 20% первичных и 70% метастатических опухолей HER2 развивается резистентность. Кроме того, авторы разработали протокол, основанный на комбинации MLPA с ddPCR для определения доли коамплифицированных HER в опухоли. На 111 IDC результаты HER2 MLPA были подтверждены FISH, CISH и IHC. Процент клеток с коамплифицированным HER2 варьировал среди опухолей. Независимые результаты in-silico показывают, что исход пациентов с HER2 обусловлен статусом HER3 и HER4. В Oncotarget результаты автора стимулировать дальнейшие исследования для изучения взаимосвязи с ответом пациента на одного или комбинированное лечение. hospitals in usa clinics in usa usa clinics lists usa hospitals lists

When public refer to today’s medicine, precision plays one of the most significant roles and people’s lives are directly dependent on it. Likewise, any researches related to medicine are required to comply with the highest standards. The problem today is that any outcomes of researches can be shared online and used as a reference without being thoroughly checked and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and attempted to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The key principle of this journal is related to Altmetric scores that are used as a quality indicator. That helps both readers and authors to quality-check publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website has a full publications list with corresponding scores above 100

Oncotarget опубликовал « Метаболическое перепрограммирование клеток глиобластомы с помощью L-аспарагиназы, сенсибилизирует апоптоз in vitro и in vivo », в котором сообщается, что результаты предполагают, что некоторые культуры клеток глиомы особенно чувствительны к ингибированию пролиферации L-аспарагиназой, в то время как другие демонстрируют более устойчивую фенотип. В чувствительных клетках L-аспарагиназа вызывает апоптоз с диссипацией митохондриального мембранного потенциала и активацией эффекторных каспаз. Учитывая влияние L-аспарагиназы на эти молекулы, исследователи обнаружили, что L-аспарагиназа эффективно преодолевает устойчивость как к внутреннему апоптозу, индуцированному ингибитором Bcl-2 / Bcl-xL, ABT263, так и к внешнему апоптозу, опосредованному TRAIL, даже в клетках глиомы, которые устойчивы к однократной обработке L-аспарагиназой. In vivo комбинированное лечение ABT263 и L-аспарагиназой привело к усиленному снижению роста опухоли по сравнению с каждым реагентом по о

When people speak of today’s medicine, precision plays one of the most important roles and human lives are literally dependent on it. Likewise, any researches related to medicine are necessary to meet the highest standards. The issue today is that any conclusions of researches can be shared online and used as a reference without being properly checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and decided to develop an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality measure. That allows both readers and authors to quality-check publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication". Oncotarget website demonstrates a complete publications list with corresponding scores higher tha

When people mention today’s medicine, precision plays one of the most important roles and people’s lives are directly dependent on it. Hence, any researches pertaining to medicine are necessary to comply with the highest standards. The issue nowadays is that any conclusions of researches can be published online and used as a reference without being thoroughly checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this challenge and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality measure. That helps both readers and authors to verify publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website has a full publications list with respective scores above 100 a

Oncotarget опубликовал статью « BIM опосредует апоптоз, индуцированный инактивацией онкогенов в моделях острого лимфобластного лейкоза на множестве трансгенных мышей », в котором сообщалось, что BIM опосредует апоптоз, индуцированный инактивацией онкогенов, в моделях острого лимфобластного лейкоза на множестве трансгенных мышей. Д-р Дин В. Фельшер из Стэнфордского университета и член редакционного совета-учредителя Oncotarget сказал: « Хотя рак развивается в рамках многоступенчатого процесса с накоплением как генетических, так и эпигенетических изменений, многие виды рака зависят от определенных онкогенов-драйверов для поддержания злокачественности ». Инактивация онкогенов-драйверов в моделях рака у мышей и таргетной терапии человека часто приводит к регрессии опухоли, связанной с индукцией апоптоза. Механизм, с помощью которого инактивация онкогенов вызывает апоптоз при раке, не определен. Совсем недавно BIM вместе с другими белками семейства BCL-2 были вовлечены в механизм апоп

When public discuss contemporary medicine, precision plays one of the most crucial roles and people’s lives are directly dependent on it. Likewise, any researches related to medicine are required to meet the highest standards. The problem today is that any results of researches can be published online and used as a reference without being thoroughly checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and decided to generate an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality measure. That assists both readers and authors to validate publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a full publications list with corresponding scores above 100 as

Oncotarget published "Llgl1 prevents metaplastic survival driven by epidermal growth factor dependent migration" which reported that We have previously demonstrated that Llgl1 loss results in a gain of mesenchymal phenotypes and a loss of apicobasal and planar polarity. Cells lacking Llgl1 form mammospheres, where survival and transplantability is dependent upon the Epidermal Growth Factor Receptor. Additionally, Llgl1 loss allows cells to grow in soft-agar and maintain prolonged survival as orthotopic transplants in NOD-SCIDmice. The loss of Llgl1 drives EGFR mislocalization and an EGFR mislocalization point mutation drives these same phenotypes, including activation of AKT and TAZ nuclear translocation. Together, these data in this Oncotarget study indicate that the loss of Llgl1 results in EGFR mislocalization, promoting pre-neoplastic changes. Dr. Joyce Schroeder from The University of Arizona said, "Epithelial cells are regulated by apicobasal polarity complex

When people discuss modern medicine, precision plays one of the most important roles and people’s lives are directly dependent on it. Hereby, any researches related to medicine are necessary to meet the highest standards. The issue today is that any outcomes of researches can be shared online and used as a reference without being adequately verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this issue and decided to come up with an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The main principle of this journal is related to Altmetric scores that are used as a quality indicator. That helps both readers and authors to quality-check publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a complete publications list with respective scores higher than